Pulmonary arterial hypertension (PAH) is a rare—albeit deadly—disease that affects the arteries of the lung. In PAH, abnormal growth of cells of the vascular media—or the elastic wall—of the pulmonary arteries, called ...
Aug 7, 2020
0
4
A novel treatment algorithm for pulmonary arterial hypertension is launched today in new pulmonary hypertension guidelines from the European Society of Cardiology (ESC) and European Respiratory Society (ERS). The protocol ...
Aug 29, 2015
0
4
Every day, 78 Canadians receive a diagnosis of lung cancer, the most deadly form of cancer in the country. Some of them will have one of the lobes of a lung removed by thoracotomy, a common, but risky surgical procedure that ...
May 4, 2019
0
4
New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...
Jan 18, 2016
0
1
Treatment for infants who have severe pulmonary arterial hypertension (PAH) is sometimes limited. Because they haven't physically matured, a procedure could increase the risk of serious complications, including failure of ...
Feb 22, 2024
0
0
National efforts are underway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD); however, new research suggests that COPD readmissions may be related to risk factors that cannot be modified, including ...
Oct 22, 2012
0
1
A group of Johns Hopkins physicians and researchers today published an article in the Journal of Hospital Medicine suggesting that data on mortality and hospital readmission used by the United States Centers for Medicare ...
Sep 1, 2016
0
0
Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, ...
Apr 28, 2016
0
10
The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.
Mar 15, 2014
0
0
Researchers at Saint Louis University School of Medicine have discovered a novel interaction between prostacyclin (PGI2) analogs and phosphodiesterase 5 (PDE5) inhibitors, two groups of drugs used in the treatment of pulmonary ...
Sep 20, 2013
0
0
